Ashish Dhir

Background

About Ashish Dhir

I possess over 15 years of research experience in drug discovery and development. I bring expertise in key areas of preclinical research, demonstrating a successful track record in drug discovery acquired from both industry and academia. My proficiency extends to devising strategies and innovating the design of pharmacology and toxicology studies for small molecules and biologicals, including immunotherapy. I hold certification as an NCA Analyst and PK/PD modelling (Phoenix WinNonLin). I have hands-on experience in drafting IND sections (pharmacology and toxicology, GIP) with the goal of initiating First-in-human clinical trials. During my tenure at Merck Animal Health, I expanded my drug discovery capabilities in the veterinary sector, contributing to the design of efficacy and safety studies for INAD (Investigational New Animal Drugs) applications. I am honored to have received the Young Investigator Award twice from the International School of Neuropsychopharmacology during meetings held in Munich (Germany) and Vancouver (Canada). Recently elected as a Fellow of American Epilepsy Society (FAES). My profile is complemented by excellent interpersonal skills, making me an effective team member. I bring a wealth of professional experience collaborating with industries, CROs, and other partners. For further details and a comprehensive list of my publications, please refer to my profile on Google Scholar: & hl=en Specialties: Preclinical pharmacology and Toxicology, Hand-on experience working with animals, Drug discovery (human and veterinary products), Product Development, knowledge of ICH guidelines, Pharmacokinetic analysis (WinNonLin/Phoenix), Business Development, Pre-IND briefing package and IND writing. Areas: Epilepsy Research: In-vivo preclinical models, Behavioral pharmacology, Refractory epilepsy models (induced by organophosphates and other toxic chemicals), animal models of epileptogenesis (spontaneous recurrent seizures), Performing EEG in animals and analysis, study of anti-seizure (and/or anti-epileptogenic) molecules and understand their mechanism with special focus on neurosteroids, AMPA receptor blockers, benzodiazepines, cannabinoids. Anticancer drug development: Cell therapy, Immunotherapy, small molecules, Diagnostic agents